Quantcast

Latest REGENERX BIOPHARMACEUTICALS INC. Stories

2014-09-03 08:34:42

ROCKVILLE, Md., Sept. 3, 2014 /PRNewswire/ -- RegeneRx Biopharmaceuticals, Inc. (OTC: RGRX) ("the Company" or "RegeneRx") today announced that it received a payment of $1 million, representing the last tranche of a $2.5 million product license and securities purchase agreement with G-treeBNT Co., Ltd, to develop RegeneRx's RGN-259 preservative-free eye drop product candidate in Asia (excluding China, Hong Kong, Taiwan, and Macau), and its RGN-137 topical dermal gel product candidate...

2008-11-04 09:00:30

REGENERX BIOPHARMACEUTICALS, INC. (AMEX:RGN) announced today that J.J. Finkelstein, RegeneRx's president and chief executive officer, will present a company update at the Rodman & Renshaw Annual Global Investment Conference in New York at 10:20 a.m. ET on Tuesday, November 11. To listen and view the presentation investors may either visit RegeneRx's homepage at www.regenerx.com or click on the following link: http://www.wsw.com/webcast/rrshq14/rgn. An archived copy of the presentation...

2008-10-24 09:00:26

REGENERX BIOPHARMACEUTICALS, INC. (AMEX:RGN) (www.regenerx.com) announced today that it is a major sponsor of "Walk a Mile in My Shoes," the signature event of National Epidermolysis Bullosa (EB) Awareness Week. The "Walk a Mile in My Shoes" program coordinates events that include rallies, meetings and walk-a-thons in an effort to raise awareness about EB. This year, the EB Medical Research Foundation and DebRA of America are again community charity partners in the program that will take...

2008-10-22 12:00:51

REGENERX BIOPHARMACEUTICALS, INC. (AMEX:RGN) announced today that J.J. Finkelstein, RegeneRx's president and chief executive officer, will present a company update at the 7th Annual BIO Investor Forum in San Francisco, CA, on Thursday, October 30, 2008 at 2:00 p.m. ET. To listen and view the presentation investors may either visit RegeneRx's homepage at www.regenerx.com or click on the following link: http://phx.corporate-ir.net/phoenix.zhtml?c=144396&p=IROL-...

2008-10-01 09:00:09

REGENERX BIOPHARMACEUTICALS, INC. (AMEX:RGN) (www.regenerx.com) announced today that it is seeking a strategic partner to assist in the development of RGN-457 for the treatment of cystic fibrosis (CF). RGN-457 is based on thymosin beta 4 (TB4) peptide formulated as an inhaled therapeutic agent to address this patient population. CF is a life-threatening, hereditary disease that impairs the patient's ability to breathe due to the accumulation of thick and sticky mucus secretions in the airways...

2008-09-22 12:00:38

REGENERX BIOPHARMACEUTICALS, INC. (AMEX:RGN) (www.regenerx.com) announced today that it has enrolled the first subject in its Phase IB clinical trial in which RGN-352 is being tested in 40 healthy subjects. RGN-352 is an injectable formulation of TB4 being developed to reduce cardiac damage in patients after an acute myocardial infarction (AMI or heart attack), as well as for other potential systemic uses. The double-blind, placebo-controlled dose-escalating trial includes four groups of ten...

2008-09-22 09:00:12

REGENERX BIOPHARMACEUTICALS, INC. (AMEX:RGN) (www.regenerx.com) announced today enrollment was completed in the second of four ongoing Phase II clinical trials. The trial is a double-blind, placebo-controlled, dose-escalating clinical trial evaluating the safety and efficacy of the Company's topical drug candidate, RGN-137, in patients with venous stasis ulcers. There are seventy-two patients being treated for up to 84 days, or less if fully healed. RegeneRx's first Phase II study, in...

2008-09-16 09:00:53

REGENERX BIOPHARMACEUTICALS, INC. (AMEX:RGN) (www.regenerx.com) announced today that researchers from Kresge Eye Institute, Wayne State University and Detroit Mercy School of Dentistry, Detroit, MI are presenting new data on TB4's ability to down-regulate inflammation in the eye at the Third Biennial Military Vision Research Symposium: Traumatic Eye and Brain Injury on September 16-18, 2008 at the Schepens Eye Research Institute, an affiliate of Harvard University, Boston, MA. The data...

2008-09-12 09:00:51

REGENERX BIOPHARMACEUTICALS, INC. (AMEX:RGN) (www.regenerx.com) announced today that Dr. Paul Riley, University College of London Institute of Child Health has been awarded the 2008 Outstanding Achievement Award of the European Society of Cardiology on Basic Cardiovascular Science. "The award made to Dr. Paul Riley, Reader in the Molecular Medicine Unit at the UCL Institute of Child Health, recognizes a landmark discovery in the field of basic cardiovascular science when his team found that...

2008-09-09 09:00:51

REGENERX BIOPHARMACEUTICALS, INC. (AMEX:RGN) (www.regenerx.com) announced today that researchers have shown that TB4 provides multi-functional protection to human gingival (gum) cells similar to its previously published activities in the eye and heart. TB4 significantly suppressed the secretion of inflammatory cells to protect gingival cells against several known toxic agents while also preventing apoptosis (cell death). "Because of its multifunctional role in protecting cells against...


Word of the Day
malpais
  • The ragged surface of a lava-flow.
'Malpais' translates from Spanish as 'bad land.'